Indegene

Which are the latest news on Indegene?

Why is Indegene Ltd falling/rising?

As of 05-Sep, Indegene Ltd's stock price is rising, currently at 600.40, with a year-to-date gain of 15.34%, outperforming the Sensex. Despite a decline in investor participation, the stock's positive financial health and strong recent performance metrics contribute to its upward trend.

As of 05-Sep, Indegene Ltd's stock price is rising, currently at 600.40, reflecting a change of 0.25 (0.04%) upwards. The stock has shown strong performance over various periods, with a 1-week increase of 3.76%, a 1-month rise of 8.37%, and a year-to-date gain of 15.34%, significantly outperforming the Sensex, which has declined by 0.97%, 2.44%, and 10.21% respectively during these periods. <BR><BR>Today's performance is also notable as the stock is just 2.6% away from its 52-week high of Rs 616 and has been gaining for the last two days, with a total return of 0.07% in that timeframe. Additionally, Indegene is trading above all its moving averages, indicating a positive trend. <BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 74.85% against the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that while participation may be falling, there is still sufficient activity in the market.<BR><BR>The company's financial health is also a contributing factor to the stock's rise, as it is net-debt free and reported positive results in June, including the highest operating cash flow at Rs 345.60 Cr and a significant growth in net sales of 21.1%. However, there are concerns regarding long-term growth, as operating profit has only grown at an annual rate of 2.93% over the last five years, and the stock is trading at a premium compared to its peers.<BR><BR>In summary, the rise in Indegene Ltd's stock price can be attributed to strong recent performance metrics, positive financial results, and favorable comparisons to the benchmark, despite some concerns regarding investor participation and long-term growth potential.

What does Indegene do?

Indegene Ltd is a small-cap healthcare services company, incorporated in 1998 and publicly listed since November 2022, with recent quarterly net sales of 1,063 Cr and net profit of 116 Cr. Key financial metrics include a P/E ratio of 35.00 and a market cap of INR 14,046 Cr.

Overview:<BR>Indegene Ltd is a healthcare services company operating in the small-cap market segment.<BR><BR>History:<BR>Indegene Limited was incorporated in 1998 as Indegene Lifesystems Private Limited in Ahmedabad, Gujarat. The company underwent several name changes, becoming Indegene Private Limited in 2016 and later converting to a public company named Indegene Limited on November 17, 2022. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,063 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 116 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 14,046 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 22 <BR>Dividend Yield: 0.38% <BR>Debt Equity: -0.43 <BR>Return on Equity: 13.27% <BR>Price to Book: 4.47 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Indegene?

Indegene's peers include Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Metropolis Health, Suven Life Sciences, Thyrocare Tech., and Vimta Labs. Most peers show below-average growth, with Thyrocare Tech. exhibiting excellent growth, while Suven Life Sciences has the highest 1-year return at 84.49%, and Syngene Intl. has the lowest at -35.90%.

Peers: The peers of Indegene are Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Metropolis Healt, Suven Life Scie., Thyrocare Tech., and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Thyrocare Tech, while Good management risk is found at Poly Medicure, Syngene Intl., Vijaya Diagnost., and the rest. Average management risk is present at Indegene, Metropolis Healt, and Vimta Labs, while Below Average management risk is noted at Suven Life Scie. Regarding growth, all peers exhibit Below Average growth, except for the Excellent growth of Thyrocare Tech. Capital Structure ratings show Excellent at Dr Lal Pathlabs, Poly Medicure, Syngene Intl., and Thyrocare Tech, Good at Metropolis Healt, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 84.49%, while Syngene Intl. has the lowest at -35.90%. Indegene's 1-year return of 12.79% is higher than Syngene Intl.'s but lower than Suven Life Scie.'s. Additionally, Metropolis Healt and Syngene Intl. have negative six-month returns.

How big is Indegene?

As of 31st August, Indegene Ltd has a market capitalization of 14,046.00 Cr, with recent net sales of 3,812.80 Cr and a net profit of 400.90 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Indegene Ltd has a market capitalization of 14,046.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,812.80 Cr, while the sum of Net Profit for the same period is 400.90 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 3,138.70 Cr and Total Assets valued at 4,543.50 Cr.

Should I buy, sell or hold Indegene Ltd?

Are Indegene Ltd latest results good or bad?

Indegene Ltd's latest results show strong revenue growth of 39.73% year-on-year, reaching ₹1,063.10 crores, and a sequential net profit increase of 45.80%. However, year-on-year net profit declined slightly, and operating margins contracted, raising concerns about operational efficiency and sustainability.

Indegene Ltd's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth of 39.73% year-on-year, with net sales reaching ₹1,063.10 crores, marking the highest quarterly revenue in its history. Additionally, there was a significant sequential improvement in net profit, which surged 45.80% from ₹79.70 crores in the previous quarter.<BR><BR>However, the profitability metrics show concerning trends. The net profit for Q1 FY27 was ₹116.20 crores, which reflects a slight decline of 0.17% year-on-year. More critically, the operating margin has contracted sharply to 16.39% from 20.41% in the same quarter last year, indicating that the company is facing challenges in translating revenue growth into profit due to rising operational costs, particularly in employee expenses.<BR><BR>Overall, while the revenue growth is strong and the sequential profit recovery is encouraging, the year-on-year margin compression and flat profit growth raise concerns about operational efficiency and sustainability. Investors should watch for signs of margin recovery in the upcoming quarters to gauge the company's ability to improve profitability alongside its revenue expansion.

When is the next results date for Indegene Ltd?

Indegene Ltd will announce its results on 29 April 2026.

Indegene Ltd is scheduled to declare its results on 29 April 2026.

Is Indegene technically bullish or bearish?

As of December 1, 2025, the technical trend is mildly bearish due to bearish momentum from the MACD and KST, daily moving averages, and Bollinger Bands, despite conflicting signals from Dow Theory and a lack of momentum indicated by the RSI.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST both indicating bearish momentum, along with daily moving averages also showing a bearish trend. The Bollinger Bands on the weekly chart confirm a bearish outlook, while the Dow Theory indicates a mildly bullish stance on the weekly timeframe, suggesting some conflicting signals. The RSI shows no signal on both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its previous close and has a significant decline over the past year.

How has been the historical performance of Indegene?

Indegene has demonstrated consistent financial growth over the past four years, with net sales increasing from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, alongside significant rises in operating profit and net profit. The company has also reduced its total debt to zero by March 2025, indicating strong overall performance.

Answer:<BR>Indegene has shown a consistent growth trajectory in its financial performance over the past four years, with significant increases in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>Indegene's net sales have risen from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, reflecting a robust growth trend. Total operating income has mirrored this increase, reaching 2,839.30 Cr in March 2025, up from 1,664.61 Cr in March 2022. The company's operating profit (PBDIT) also demonstrated substantial growth, climbing from 312.81 Cr in March 2022 to 641.50 Cr in March 2025. Profit before tax followed suit, increasing from 226.50 Cr in March 2022 to 539.30 Cr in March 2025, while profit after tax rose from 162.82 Cr to 406.70 Cr in the same period. The company's total assets have expanded significantly, from 1,284.31 Cr in March 2022 to 3,236.10 Cr in March 2025, alongside a reduction in total debt, which dropped to 0.00 Cr in March 2025 from 403.10 Cr in March 2024. Cash flow from operating activities has also been positive, amounting to 441.00 Cr in March 2025, although cash flow from investing activities was negative at -677.00 Cr. Overall, Indegene's financial metrics indicate a strong and improving performance over the years.

Who are the top shareholders of the Indegene?

The top shareholders of Indegene include Nadathur Fareast Pte Ltd with 21.96%, 18 mutual fund schemes holding 2.65%, and 72 foreign institutional investors owning 5.24%. Individual investors hold 11.34%, with no pledged promoter holdings or a single dominant promoter.

The top shareholders of Indegene include Nadathur Fareast Pte Ltd, which holds the largest public share at 21.96%. Additionally, the company has a diverse shareholder base with 18 mutual fund schemes collectively holding 2.65% and 72 foreign institutional investors (FIIs) holding 5.24%. Individual investors also have a significant presence, owning 11.34% of the shares. Notably, there are no pledged promoter holdings, and there isn't a single promoter with the highest holding.

Is Indegene overvalued or undervalued?

As of June 17, 2025, Indegene is considered undervalued with an attractive valuation grade, reflected by a PE ratio of 34.27, an EV to EBITDA of 23.16, and a strong ROCE of 43.13%, despite its higher ratios compared to peers like TCS and Infosys and a year-to-date return of -3.89% versus the Sensex's 4.41%.

As of 17 June 2025, the valuation grade for Indegene has moved from fair to attractive, indicating a more favorable outlook for the company. The current analysis suggests that Indegene is undervalued. Key ratios include a PE ratio of 34.27, an EV to EBITDA of 23.16, and a ROCE of 43.13%, which reflects strong operational efficiency.<BR><BR>In comparison to peers, Indegene's PE ratio is notably higher than TCS at 26.2 and Infosys at 25.51, while its EV to EBITDA is also above TCS's 18.32. This suggests that while Indegene is trading at a premium compared to some peers, its robust ROCE and PEG ratio of 0.00 indicate significant growth potential. Despite recent stock performance trailing the Sensex, with a YTD return of -3.89% compared to the Sensex's 4.41%, the overall valuation metrics support the conclusion that Indegene is currently undervalued.

Has Indegene declared dividend?

Indegene Ltd has declared a 100% dividend with an ex-date of June 13, 2025. However, the dividend yield is 0%, and total returns over longer periods show no growth, indicating mixed performance.

Indegene Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 13 Jun 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Indegene experienced a price return of -6.36%, a dividend return of 0.34%, resulting in a total return of -6.02%.<BR><BR>Over the past year, the company achieved a price return of 9.98%, a dividend return of 0.36%, leading to a total return of 10.34%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, Indegene reported no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Similarly, over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the company again had no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Indegene has declared a dividend, the dividend yield remains at 0%, and the total returns over longer periods show no growth, indicating a mixed performance in terms of returns.